Bioniche, Endo deal

Endo exercised an option to license exclusive, worldwide rights to Urocidin from Bioniche. Endo gained the option last year, when it licensed U.S. rights to the mycobacterial cell wall-DNA complex that is in Phase III testing for non-muscle-invasive bladder cancer. Data are expected mid-year. Endo will now be responsible for all external development costs and for conducting clinical trials (see BioCentury, July 13, 2009). ...